ORGANIZATION

• Japan Needs New Pricing Scheme for Regenerative Medicine: Industry Group
  July 31, 2025

• Japan Society Poised to Set Out Criteria to Standardize Regional Formularies, Eyes August Release
  July 31, 2025

• Takeda Alumni Link with Osaka Biz Lobby to Support Drug Discovery
  July 28, 2025

• JPMA Urges Safeguards for Patient Access in Any Future Drug Tariff Talks
  July 24, 2025

• JPMA Selected for Japan Program to Cut Carbon Emissions
  July 23, 2025

• Industry Calls for More Tailored Govt Support on Drug Loss Product Development
  July 16, 2025

• Japan Logs 11th Straight Year of Decline in Drug Reps, Voluntary Buyouts Likely a Major Factor
  July 16, 2025

• Japan’s Generic Use Rate Reaches 86.5% in FY2024: JGA
  July 7, 2025

• FPMAJ Confirms Regulatory Compliance Actions Completed for All Generic Drug Discrepancies
  July 3, 2025

• Pharma Labor Platform Calls for Inflation-Responsive Drug Pricing Reforms, Opposes CEA Expansion
  July 3, 2025

• Japan’s Contract Rep Ratio Hits Record as Biotechs, Foreign Firms Drive Demand
  July 1, 2025

• FPMAJ Chair Questions Sakigake as Incentive for Prioritizing Japan R&D
  June 24, 2025

• JGA Targets FY2027 for Resolving Drug Shortages, Two Years Ahead of Forecast
  June 20, 2025

• Generic Use Rate at 89.0% in January: Payer
  June 18, 2025

• JMA’s Upper House Candidate Says Scraping Drug Prices to Pool Resources No Longer Holds
  June 17, 2025

• 84% of Pharmacies See More Generic Dispensing after Rollout of New LLP Rule: FPMAJ
  June 17, 2025

• FPMAJ Calls for Relaxation of Support Rules for Low-Priced Drugs
  June 17, 2025

• FPMAJ Calls for Expanded Range of Selection for Comparator Drugs
  June 16, 2025

• PMP Drugs Should Be Excluded from Price Revisions: FPMAJ Committee Chief
  June 16, 2025

• JPMA Ready to Engage with Government on CEA Debates: Statement
  June 16, 2025

ページ

• « 先頭
• ‹ Prev
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »